PT-141 (Bremelanotide)

Sexual health FDA-approved drug

Cyclic heptapeptide melanocortin receptor agonist (MC3R/MC4R) · also known as Bremelanotide, Vyleesi

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Bremelanotide is a Melanotan II metabolite-derived melanocortin agonist. The US product, Vyleesi, is labeled for acquired, generalized hypoactive sexual desire disorder in premenopausal women at 1.75 mg given subcutaneously as needed. Daily escalating schedules in reference charts go beyond the labeled regimen.

Commonly reported dosing (10 mg vial)

Reconstituted with 3 mL → 3.333 mg/mL.

Phase	Dose	Volume	U-100 units
Starting Reference-chart daily figure.	500 mcg	0.15 mL	15
Standard	1 mg	0.3 mL	30
Higher	1.5 mg	0.45 mL	45
Labeled dose (approved product) Single as-needed dose in the US label; at most one dose per 24 hours and 8 per month.	1.75 mg	0.525 mL	52.5

Frequency: Labeled as needed (1.75 mg, at most one dose per 24 hours and 8 doses per month); reference charts also show daily escalation · Half-life: About 2.7 hours (US label)

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 10 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 3.33 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized research vials are commonly stored frozen (around -20 °C), dry and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C) and protected from light, with repeated freeze-thaw cycles avoided. The approved autoinjector is labeled for storage at or below 25 °C, not frozen.

How it works

Activation of melanocortin receptors, chiefly MC4R, in the central nervous system is thought to modulate sexual desire pathways; the label notes the exact mechanism for improving desire is not established.

Researched for

Two phase 3 randomized trials (RECONNECT) found improved desire and reduced distress versus placebo in premenopausal women with HSDD.
Daily 2.5 mg dosing was examined in a study of appetite and weight in women with obesity.

Notes

Label-reported effects include nausea (about 40% of participants), flushing, injection-site reactions, headache and vomiting.
The label reports transient blood-pressure increases and focal hyperpigmentation, which was far more common with daily dosing than with the labeled as-needed schedule.
The label lists uncontrolled hypertension and known cardiovascular disease as contraindications.
Brand-name pens and kits are pre-measured; the reconstitution figures here apply to vials that require mixing.